Literature DB >> 31321509

Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis.

Florian Janisch1,2, Shahrokh F Shariat3,4,5,6,7,8, Pascal Baltzer9, Harun Fajkovic1, Shoji Kimura1,10, Takehiro Iwata1,11, Philipp Korn1, Lin Yang12,13,14, Petr V Glybochko15, Michael Rink2, Mohammad Abufaraj1,16.   

Abstract

PURPOSE: To systematically review the literature evaluating the performance of MDCTU for the diagnosis of UTUC and meta-analyse available data. We also compared the diagnostic accuracy of MDCTU to other radiologic modalities.
METHODS: This systematic review and meta-analysis was conducted according to the PRISMA statement. A systematic research using Pubmed, Scopus, Cochrane, and Web of Science libraries was performed on November 1st, 2018. We included all original articles investigating the performance of MDCTU for the diagnosis of UTUC using histopathology as the reference standard for true positives and an unsuspicious clinical follow-up of at least 1 year for true negatives.
RESULTS: Overall, 13 studies comprising 1233 patients were eligible and included in this systematic review and meta-analysis. In patient-based analyses, the pooled sensitivity and specificity were 92% (CI 0.85-0.96) and 95% (CI 0.88-0.98), respectively. The reported sensitivity in the per-lesion analysis ranged between 91 and 97%. All studies reporting segment-based analysis demonstrated high diagnostic accuracy (> 90%). While one study reported higher accuracy of retrograde ureteropyelography than MDCTU (97% vs. 94%), another study demonstrated an inferior accuracy of intravenous pyelogram compared to MDCTU. Findings on the accuracy of diffusion-weighted magnetic resonance imaging compared to MDCTU were inconsistent.
CONCLUSION: MDCTU has excellent diagnostic performance in detecting UTUC and ruling-out suspicious upper urinary tract lesions in per-patient and per-lesion-based analyses. We confirm the choice of MDCTU as the radiologic diagnostic modality of choice for work-up of suspicious upper urinary tract lesions providing valuable information in patient counseling, decision-making, and treatment planning.

Entities:  

Keywords:  Diagnostic accuracy; Imaging; MDCTU; Meta-analysis; Systematic review; UTUC

Mesh:

Year:  2019        PMID: 31321509     DOI: 10.1007/s00345-019-02875-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  13 in total

1.  Diagnostic performance of fluorescence in situ hybridization (FISH) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis.

Authors:  Amir Hossein Aalami; Farnoosh Aalami
Journal:  Int J Clin Oncol       Date:  2022-07-18       Impact factor: 3.850

Review 2.  Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.

Authors:  Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk
Journal:  Nat Rev Urol       Date:  2022-03-31       Impact factor: 16.430

Review 3.  Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Michael Rink; David D'Andrea; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Turk J Urol       Date:  2020-10-09

Review 4.  Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe?

Authors:  Angelo Territo; Andrea Gallioli; Iacopo Meneghetti; Matteo Fontana; Jordi Huguet; Joan Palou; Alberto Breda
Journal:  Arab J Urol       Date:  2021-02-16

Review 5.  CT Urography Findings of Upper Urinary Tract Carcinoma and Its Mimickers: A Pictorial Review.

Authors:  Paola Martingano; Marco F M Cavallaro; Alessandro M Bozzato; Elisa Baratella; Maria A Cova
Journal:  Medicina (Kaunas)       Date:  2020-12-17       Impact factor: 2.430

6.  Ex Vivo Near-Infrared Molecular Imaging of Human Upper Urinary Tract Urothelial Carcinoma With a CD47-Based Targeted Tracer.

Authors:  Pengyu Yan; Dan Chen; Xutao Yan; Xiaoting Yan; Yingpeng Wang; Chao Liu; Xiaofeng Yang
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

Review 7.  MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?

Authors:  Alessandra Cinque; Anna Capasso; Riccardo Vago; Matteo Floris; Michael W Lee; Roberto Minnei; Francesco Trevisani
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

8.  Diagnostic Ureteroscopy in CT Urography-Diagnosed Upper Tract Urothelial Carcinoma: Delay in Definitive Treatment and Increased Intravesical Recurrence.

Authors:  Hadi Shsm; Elizabeth Bright; Mark Mantle; Nicholas Munro; Omar Fahmy
Journal:  Cureus       Date:  2021-06-20

9.  Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration.

Authors:  Keiichiro Mori; Irene Resch; Noriyoshi Miura; Ekaterina Laukhtina; Victor M Schuettfort; Benjamin Pradere; Satoshi Katayama; David D'Andrea; Mehdi Kardoust Parizi; Mohammad Abufaraj; Wataru Fukuokaya; Claudia Collà Ruvolo; Stefano Luzzago; Sophie Knipper; Carlotta Palumbo; Pierre I Karakiewicz; Alberto Briganti; Dmitry V Enikeev; Morgan Rouprêt; Vitaly Margulis; Shin Egawa; Shahrokh F Shariat
Journal:  Cancer Immunol Immunother       Date:  2021-02-16       Impact factor: 6.968

10.  Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

Authors:  David D'Andrea; Surena Matin; Peter C Black; Firas G Petros; Homayoun Zargar; Colin P Dinney; Michael S Cookson; Wassim Kassouf; Marc A Dall'Era; John S McGrath; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeffrey M Holzbeierlein; Trinity J Bivalacqua; Srikala S Sridhar; Scott North; Daniel A Barocas; Yair Lotan; Andrew J Stephenson; Bas W van Rhijn; Philippe E Spiess; Siamak Daneshmand; Shahrokh F Shariat
Journal:  BJU Int       Date:  2020-10-14       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.